Journal article Open Access

Systematic evaluation of the effects of metformin on the mTOR signalling pathway in the treatment of spinal cord injury

Yasin Emre Kaya

MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="">
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Metformin; mTOR  ignalling pathway, rapamycin; spinal cord injury, sirolimus</subfield>
  <controlfield tag="005">20200120173127.0</controlfield>
  <controlfield tag="001">2550818</controlfield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">161093</subfield>
    <subfield code="z">md5:a5d87a0c1cebc1ef2e598c5a301db164</subfield>
    <subfield code="u"> pdf.docx</subfield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2019-01-27</subfield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire</subfield>
    <subfield code="o"></subfield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">Assist. Prof. M.D.; Abant Izzet Baysal University School of Medicine, Department of Orthopaedic and Traumatology, 14030, Bolu, Turkey</subfield>
    <subfield code="a">Yasin Emre Kaya</subfield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Systematic evaluation of the effects of metformin on the mTOR signalling pathway in the treatment of spinal cord injury</subfield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u"></subfield>
    <subfield code="a">Creative Commons Attribution 4.0 International</subfield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2"></subfield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;&lt;strong&gt;Metformin is one of the safest drugs used to control blood sugar in diabetes. This drug is being investigated by orthopedists as well as by neurosurgeons as it may increase the locomotor recovery after spinal cord injury (SCI). In the present study, the aim was to evaluate a promising pharmacological agent, metformin, which is known to be used in SCI treatment by acting over the mammalian target of rapamycin (mTOR) and some other signaling pathway. Relevant clinical trials were included in the study following electronic database scan. &amp;nbsp;Preclinical and cellular studies have demonstrated that metformin may have antitumoral properties, regulate inflammation, and therefore play a role in the tumor microenvironment, or that it has a therapeutic effect in SCI by acting over mTOR pathway. However, Level of I clinical trials should be performed to determine the effectiveness of metformin in SCI, a serious pathology.&lt;/strong&gt;&lt;/p&gt;</subfield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="n">doi</subfield>
    <subfield code="i">isVersionOf</subfield>
    <subfield code="a">10.5281/zenodo.2550817</subfield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.5281/zenodo.2550818</subfield>
    <subfield code="2">doi</subfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
All versions This version
Views 6868
Downloads 44
Data volume 644.4 kB644.4 kB
Unique views 6565
Unique downloads 44


Cite as